يعرض 1 - 20 نتائج من 1,274 نتيجة بحث عن '"Favourable"', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
  5. 5
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal

    المساهمون: Física Aplicada

    المصدر: Science of the Total Environment, Vol. 898, 2023

    وصف الملف: application/pdf

    Relation: info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-100865-B-C22/ES/CIRCULACION Y PROCESOS DE TRANSPORTE EN LOS ESTUARIOS DEL GOLFO DE CADIZ: SITUACION ACTUAL Y/; info:eu-repo/grantAgreement/AEI//PID2021-128656OB-I00; http://hdl.handle.net/10498/31722

  19. 19
    Academic Journal

    المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 80-86 ; Медицинский Совет; № 22 (2023); 80-86 ; 2658-5790 ; 2079-701X

    وصف الملف: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/7983/7070; Piao X-M, Byun YJ, Zheng C-M, Song SJ, Kang HW, Kim WT et al. A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC. Cancers. 2023;15(3):935. https://doi.org/10.3390/cancers15030935.; Волкова МИ, Алексеев БЯ, Гладков ОА, Матвеев ВБ, Носов ДА. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли. 2022;12(3s2-1):579–588. https://doi.org/10.18027/2224-5057-2022-12-3s2-579-588.; Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ et al. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2022;40(25):2957–2995. https://doi.org/10.1200/JCO.22.00868.; Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82(4):399–410. https://doi.org/10.1016/j.eururo.2022.03.006.; Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405–415. https://doi.org/10.1016/S1470-2045(18)30081-0.; Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714.; Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol. 2023;41(17 Suppl.):LBA4501. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501.; Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573. https://doi.org/10.1016/S1470-2045(20)30436-8.; Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. Eur Urol. 2023;84(5):449–454. https://doi.org/10.1016/j.eururo.2023.06.006.; Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncol. 2019;15(9):929–941. https://doi.org/10.2217/fon-2018-0745.; Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289–1300. https://doi.org/10.1056/NEJMoa2035716.; Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228–238. https://doi.org/10.1016/S1470-2045(23)00049-9.; Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2023;41(16 Suppl.):4502. https://doi.org/10.1200/JCO.2023.41.16_suppl.4502.; Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M et al. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Eur Urol Oncol. 2023;6(4):437–446. https://doi.org/10.1016/j.euo.2023.01.010.; Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023;13:1223282. https://doi.org/10.3389/fonc.2023.1223282.; Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047.; Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039. https://doi.org/10.1016/j.annonc.2020.04.010.; Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB et al. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023;8(3):101210. https://doi.org/10.1016/j.esmoop.2023.101210.; Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021;384(9):829–841. https://doi.org/10.1056/NEJMoa2026982.; Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888–898. https://doi.org/10.1016/S1470-2045(22)00290-X.; Burotto M, Powles T, Escudier B, Apolo AB, Bourlon MT, Shah AY et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. J Clin Oncol. 2023;41(6 Suppl.):603. https://doi.org/10.1200/JCO.2023.41.6_suppl.603.; Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol. 2022;32(1):61–68. https://doi.org/10.1097/MOU.0000000000000940.; Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy. 2022;14(2):145–153. https://doi.org/10.2217/imt-2021-0157.; Hou M, Xing H, He S, Yang X, Peng D, Li Y et al. The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. J Oncol. 2022;2022:7733251. https://doi.org/10.1155/2022/7733251.; Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E et al. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;5(5):CD013798. https://doi.org/10.1002/14651858.CD013798.pub2.; Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D et al. The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer. BMC Cancer. 2012;12(1):598. https://doi.org/10.1186/1471-2407-12-598.; Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023;24(3):213–227. https://doi.org/10.1016/S1470-2045(22)00793-8.; Parikh M, Lara PN. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer. 2022;6(2):105–107. https://doi.org/10.3233/KCA-229003.; Tzeng A, Tzeng TH, Ornstein MC. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer. 2021;9(10):e003473. https://doi.org/10.1136/jitc-2021-003473.; https://www.med-sovet.pro/jour/article/view/7983

  20. 20
    Academic Journal